Therefore, it could be reasonably speculated that the efficacy of rituximab in preventing the occurrence of poor outcomes of MPA, particularly progression to ESKD during follow-up, might be greater in MPA patients having a higher titre of MPO-ANCA. Here, MPO is linked to microscopic polyangiitis.